(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro. Read More
(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc. Read More
(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower. Read More
IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment." Read More
IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. Read More
IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Corrects that Zenith Energy is based in Canada, not in Scotland.) Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
IQ-AI Ltd - Jersey-based medical services firm - Posts larger interim pretax loss due to increased administrative costs. Pretax loss in the half-year to June 30 widens to GBP330,584 from GBP207,135 a year ago. Revenue climbs 7.2% to GBP255,609 from GBP238,488. However, revenue growth is offset by administrative costs increasing by 34% to GBP583,346 from GBP436,247. Read More
IQ-AI Ltd - Jersey-based medical services firm - Says its medical imaging analysis software, IB Clinic, is now available via the newly launched Bayer Calantic platform. The distribution partnership continues its strategy of making IB Clinic accessible to healthcare providers through widespread networks, the company adds. Read More
IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC submits 510(k) application to US Food & Drug Administration for IB Zero G, an artificial intelligence software that eliminates the need for gadolinium-based contrast agents in routine magnetic imagining exams. "The FDA 510(k) submission is the first step in potentially transforming the global gadolinium-based contrast agent market and introducing a paradigm shift in radiology departments," company says. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. Read More
(Alliance News) - IQ-AI Ltd unit Imaging Biometrics on Tuesday said a study concluded its imaging technology was successful in identifying tumours. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
IQ-AI Ltd - Jersey-based medical services firm - Says phase one clinical trial for oral gallium maltolate is open for enrolment. Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified, it notes. Phase one dose escalation study is designed to determine the optimal dose of GaM that can be administered safely. It is the first-in-human clinical trial for an oral form of GaM to be used in patients with high-grade brain tumours, it adds. Read More
TRADING UPDATES: Beximco profit rises; Tremor buoyant as sales rise Read More